Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04924101
Title Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.

lung small cell carcinoma


Cisplatin + Etoposide + Lenvatinib + Pembrolizumab

Carboplatin + Etoposide + MK-5890 + Pembrolizumab

Carboplatin + Etoposide + Lenvatinib + Pembrolizumab

Carboplatin + Etoposide + MK-4830 + Pembrolizumab

Cisplatin + Etoposide + MK-5890 + Pembrolizumab

Cisplatin + Etoposide + MK-4830 + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | ITA | ESP | CAN | AUT

No variant requirements are available.